5-FU AS AN ADJUVANT TO MASTECTOMY IN HIGH-RISK PATIENTS

被引：0
|
作者：
ANSFIELD, FJ [1 ]
机构：
[1] UNIV WISCONSIN,MADISON,WI 53706
来源：
PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH | 1974年 / 15卷 / MAR期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：177 / 177
页数：1
相关论文
共 50 条
  • [21] Cerebral demyelination during adjuvant treatment with fluorouracil (5-FU) and Levamisole
    Galassi, G
    Tassone, G
    Marchi, M
    Sintini, M
    Santini, A
    Mavilia, L
    BRAIN PATHOLOGY, 1997, 7 (04) : 1081 - 1081
  • [22] RADIOTHERAPY FOR THE PREVENTION OF LOCAL-REGIONAL RECURRENCE IN HIGH-RISK PATIENTS POST MASTECTOMY RECEIVING ADJUVANT CHEMOTHERAPY
    FOWBLE, B
    GLICK, J
    GOODMAN, R
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1988, 15 (03): : 627 - 631
  • [23] 5-FU CARDIOTOXICITY
    SANANI, S
    SPAULDING, MB
    MASUD, ARZ
    CANTY, R
    CANCER TREATMENT REPORTS, 1981, 65 (11-1): : 1123 - 1125
  • [24] Effects of 5-FU
    Wigmore, Peter M.
    Mustafa, Sarah
    El-Beltagy, Maha
    Lyons, Laura
    Umka, Jariya
    Bennett, Geoff
    CHEMO FOG: CANCER CHEMOTHERAPY-RELATED COGNITIVE IMPARIMENT, 2010, 678 : 157 - 164
  • [25] Prodrugs of 5-FU
    Kaye, SB
    ANNALS OF ONCOLOGY, 1998, 9 : 23 - 23
  • [26] The cost of 5-FU
    Ryan, RF
    PLASTIC AND RECONSTRUCTIVE SURGERY, 2001, 107 (06) : 1613 - 1613
  • [27] 5-FU: finally!
    Robert, Jacques
    BULLETIN DU CANCER, 2019, 106 (03) : 173 - 174
  • [28] PSYCHIATRIC MORBIDITY FOLLOWING MASTECTOMY - THE IDENTIFICATION OF PATIENTS AT HIGH-RISK
    WHITFORD, P
    MCARDLE, JMC
    MCARDLE, CS
    BRITISH JOURNAL OF SURGERY, 1986, 73 (06) : 504 - 504
  • [29] 5-FU schedules, serum 5-FU levels and their relationship to therapy response and toxicity in patients with gastrointestinal cancer
    Blaschke, Martina
    Cameron, Silke
    Goeschen, Colin
    Ramadori, Giuliano
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2013, 51 (01) : 56 - 58
  • [30] Two Pan-European trials in adjuvant colon cancer (PETACC 1&2):: The efficacy of Tomudex® compared to bolus 5-Fluorouracil/leucovorin (5-FU/LV); and high dose infusional 5-FU compared to bolus 5-FU/LV, in patients with stage III colon cancer
    Wils, J
    ANNALS OF ONCOLOGY, 1998, 9 : 45 - 45
12345